Uses
AGX51 is the first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader. AGX51 inhibits Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and viability reduction. AGX51 can inhibit TNBC and has an IC50 of about 25 nM. AGX51 can be used in cancer research.
Biological Activity
AGX51 is an antagonist th at blocks transcriptional regulators ID1-4 from binding basic helix-loop-helix (bHLH) transcription factor E47, causing ubiquitin-mediated degradation of IDs (10-40 μM for 2-48h; HCT116). AGX51 reduces cell viability, G0/G1 growth arrest, and a reduction in cyclin D1 levels in cultures (5-40 μM for 4-24h; HUVEC and HCT116) and suppresses ocular neovascularization in mouse models of age-related macular degeneration (AMD) and retinopathy of prematurity (ROP) in vivo (500 μg/mouse via twice daily i.p. or 1-30 μg/eye via intravitreal injection immediately and 7 days after rupture of Bruch's membrane).
in vivo
AGX51 (50 mg/kg; i.p. twice a day for 4 weeks) inhibits lung metastasis[1].
AGX51 (15 mg/kg; i.p. twice a day for 3 weeks) exibits anti-tumor activity with autochronous cancer[1].
| Animal Model: | Balb/c mice with luciferase-labeled 4T1 cells[1] |
| Dosage: | 50 mg/kg |
| Administration: | Intraperitoneal injection; 60 mg/kg twice a day; for 4 weeks |
| Result: | Inhibited lung metastasis development. |
| Animal Model: | A/J mice with AOM colon tumor model[1] |
| Dosage: | 15 mg/kg |
| Administration: | Intraperitoneal injection; 15 mg/kg twice a day; for 3 weeks |
| Result: | Dreased the colon tumors and exhibited anti-tumor activity in AOM colon tumor mice. |
References
[1] Wojnarowicz PM, et al. Anti-tumor effects of an ID antagonist with no observed acquired resistance. NPJ Breast Cancer. 2021 May 24;7(1):58. DOI:
10.1038/s41523-021-00266-0
![N-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-N-benzylpropanamide Structure](https://www.chemicalbook.com/CAS/20180723/GIF/330834-54-3.gif)
